Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVax-L in Newly Diagnosed Glioblastoma
NCT00045968Phase 3Unknown
- Sponsor
- Northwest Biotherapeutics
- Start
- Dec 2006
- Primary completion
- Nov 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 4
01
Overview
A Phase 3 trial of DCVax-L in glioblastoma (GBM), sponsored by Northwest Biotherapeutics. Status: unknown.
02
Drugs
DCVax-L
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00045968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045968.